5 results
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
We estimate that the anthracycline and cyclophosphamide dose could be significantly (>=15%) increased in at least 15% of ACC-treated patients. Therefore, in order to diminish the risk of under-dosing ACC, we aim to develop a neutrophil-guided…
To confirm safety and performance of the G7 BiSpherical Acetabular Shell.
This study is a PMCF study to fulfill the post-market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2. The data collected from this study will serve the purpose of confirming safety and performance of the G7…